The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...

Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with symptomatic obstructive ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced.

Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...

Background The National Heart Failure Audit gathers data on patients coded at discharge (or death) as having heart failure as ...

Objective Heart failure (HF) is common with high associated morbidity and mortality. UK National Institute for Health and ...

What your blood pressure really says about your health – and why it’s worth tracking Your sleep score is consistently high, ...

Discover Peripartum Cardiomyopathy (PPCM), a life-threatening heart condition that affects new mothers during or after ...